作者：春兰秋桂

本文为作者授权医脉通发布，未经授权请勿转载。

患者确诊为急性白血病、骨髓增生异常综合征（MDS）后，如何预判疗效、合理选择高效治疗方案，预后分层系统在其中起重要作用。本文旨在汇总急性白血病和MDS中临床最常用预后分层系统，供大家在日常临床实践中参考。

MDS临床常用预后分层系统包括IPSS、IPSS-R及WPSS

IPSS^[1]

IPSS-R^[2]

WPSS^[3-4]

急性髓系白血病（AML）临床常用预后分层系统^[5]

B细胞急性淋巴细胞白血病（B-ALL）细胞遗传学危险分组^[6]

参考文献：

[1] Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088; Erratum. Blood 1998;91:1100.

[2] Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465.

[3] Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndromes and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433-1440.

[4] Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classificationbased Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWGPM). Leukemia 2015;29:1502-1513.

[5] Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424-447.

[6] NCCN Guidelines Version 2.2019. Acute Lymphoblastic Leukemia.

(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)